Revenue
Margin
Demand
Guidance
Tone
Metrics raised 1
- Blended capacity utilization target raised to 35–40% (from ~30% YTD Dec)
Event Participants
Executives
3 Dr. Nikhil Kelkar (Joint Managing Director), Mr. Soman Jana (Chief Financial Officer), Mr. Vikram Kelkar (Managing Director)
Analysts
9 Abhishek Maheshwari, Dhanesh, Makool Agarwal, Nikhil Gupta, Nitin Khandkar, Prerak Gandhi, Saket Kapoor, Shravan, Urvija Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue from Operations | ₹382.63 crores (FY26) | +17.8% YoY vs ₹324.93 crores; driven by sustained demand across domestic and international markets |
| Q4 Revenue from Operations | ₹115.04 crores | Continued demand momentum across both domestic and international markets in the quarter |
| EBITDA | ₹52.90 crores (FY26) | +32.01% YoY; margin expanded 150 bps to 13.83% (from 12.33%) on operating leverage, better product mix and manufacturing efficiencies |
| Q4 EBITDA | ₹15.35 crores | Q4 margin of 13.34% |
| PAT | ₹37.94 crores (FY26) | +56.1% YoY vs ₹24.31 crores; PAT margin improved 240 bps to 9.9% (from 7.5%) |
| Q4 PAT | ₹10.9 crores | Q4 PAT margin of 9.5% |
| Export Share of Revenue | 57% of FY26 revenue | >80% of exports from premix + ESG segments, balance from branded exports; West Asia <20% of total exports |
| Segment Revenue Mix (FY26) | Branded ~30%; Premix ~35–40%; ESG ~30% | Diversified across three verticals; segment margins: branded 60–68%, premix 35–40%, ESG 25–30% |
| Trade Receivables | ₹82 crores | Up from ₹60 crores YoY due to large ESG orders dispatched in Q3/Q4 and domestic premix orders in Q4; management states cyclical and now normalized |
| Blended Capacity Utilization | ~30% (YTD Dec) → 35–40% expected | Segment-wise: branded 50–60%, premix 40–45%, ESG 35–40% (can touch 60%); buffer retained for future tenders |
Geographic & Segment Commentary
- Micronutrient Premixes (~35–40% of revenue): B2B blends of vitamins, minerals and nutritional ingredients supplied to food manufacturers and pharma companies. Segment margins of 35–40%. Growing demand from fortified foods, preventive healthcare, and nutritionally enhanced food categories; customers increasingly expect customized formulations driven by scientific expertise.
- Branded / Consumer & Clinical Nutrition (~30% of revenue): Includes PentaSure (12 brand extensions), PediaGold (paediatric) and Obesigo (weight management). Segment margins of 60–68%, the highest in the portfolio. Management estimates the Indian clinical nutrition market at ~₹6,300 crores, leaving significant headroom. Growth strategy centres on expanding medical representative footprint into Tier 2/3 cities, distribution network expansion, and e-commerce scale-up.
- ESG / Therapeutic Foods & Food Fortification (~30% of revenue): Covers ready-to-use therapeutic foods (RUTF), ready-to-use supplementary foods (RUSF) and micronutrient powders supplied largely through UN and government tenders. Segment margins of 25–30%. Management reports a healthy order pipeline for tender-based business; capacity utilization varies with order flow (35–40%, sometimes 60%).
- International Footprint: Wholly owned subsidiaries in South Africa, Uzbekistan, and Hong Kong support exports, which comprise 57% of revenue. Imports for raw materials are <25% of total requirement, sourced from China, Singapore, Korea and Europe; management confirmed no significant supply chain disruption from the West Asia conflict.
Company-Specific & Strategic Commentary
- IPO & Listing: Successfully listed on NSE and BSE during FY26; management emphasized commitment to governance, transparency, and ongoing investor engagement as a listed entity.
- Branded Segment Growth Plan: Expanding feet-on-ground via larger medical representative teams, deeper Tier 2/3 city coverage, parallel distribution network expansion, and e-commerce presence across Amazon, Flipkart, e-pharmacies, and the company's own website — supported by social media, digital marketing, and medical marketing (conferences, CME/CNE programs).
- Product Differentiation & R&D: R&D positioned as the company's backbone; products differentiated via multi-protein blends offering distinct amino acid profiles versus MNC competitors (Abbott, Nestle, Fresenius Kabi). New product launches expected in the upcoming period.
- Manufacturing & Quality: Facilities in Nashik (Maharashtra) and Chennai (Tamil Nadu); capacity buffer deliberately retained for unanticipated tender orders; operational excellence, process discipline, and quality embedded as cultural priorities.
- Raw Material Strategy: Imports (<25% of requirement) include Vitamin A, B-group vitamins, Vitamin C, and folic acid; strategic inventory building for vitamins and MRP-based pass-through for inputs like whey mitigate price volatility.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue Growth | Maintain historical momentum of ~15–20% (revenue doubling every 4–5 years) | Management confirmed doubling revenue over a 4–5 year horizon is a "correct estimate"; war situation has not negatively impacted business so far |
| EBITDA Margin | Further expansion expected | Operating leverage to improve as revenue scales; management declined to quantify a specific margin target |
| Capacity Utilization | Expected to improve to 35–40% blended | Supported by positive growth across all major segments (branded 50–60%, premix 40–45%, ESG 35–40%); buffer maintained for tenders |
| Segment Margins | Branded 60–68%; Premix 35–40%; ESG 25–30% | Structural margin profile by segment; mix shift toward branded is the key margin lever |
| Branded Portfolio | Increased FY27 focus on PediaGold and Obesigo | Both brands underpenetrated vs PentaSure; paired with Tier 2/3 expansion and all-India promotion |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical Exposure (West Asia) | Exports to West Asia constitute <20% of total exports; management states no significant impact to date because food ingredients remain essential procurement. Demand continuity should be monitored if conflict escalates. |
| Raw Material Price Volatility | Rising whey prices noted; branded segment can pass through via MRP increases. Vitamins and other ingredients are procured with strategic inventory, but sustained input inflation could pressure margins if pass-through lags. |
| Import Concentration | <25% of raw material requirements imported from China, Singapore, Korea, and Europe (notably Vitamin A, B-group vitamins, Vitamin C, folic acid). No supply chain issues currently, but geopolitical/trade disruptions in these regions remain an external risk. |
| Capacity Underutilization | Blended utilization at ~30% (YTD December) reflects demand variability, particularly in tender-driven ESG segment. While this creates operating leverage headroom, it also indicates dependence on UN/government tender order flow. |
| Receivables & Tender Cyclicality | Trade receivables rose from ₹60 crores to ₹82 crores due to Q3/Q4 ESG and premix dispatches. Management says normalized and cyclical, but lumpy tender orders can periodically elevate working capital. |
Q&A Highlights
Export Revenue & Geographic Mix
- Question: Can you bifurcate the 57% export revenue by product category, and is there exposure to war-affected regions? (Abhishek Maheshwari)
- Answer: More than 80% of export revenue comes from premixes and the ESG segment, with the balance from branded exports. Exports to West Asia are less than 20% of total exports, so the war has not significantly impacted the business; food ingredients remain essential procurement for every country. (Vikram Kelkar)
Raw Material Sourcing & Supply Chain
- Question: Where are key raw materials sourced from, and are there supply chain issues amid the war? (Abhishek Maheshwari)
- Answer: Imports are less than 25% of total requirements, sourced mainly from China, Singapore, Korea, and Europe — primarily vitamins such as Vitamin A, B-group vitamins, Vitamin C, and folic acid. No significant sourcing challenges have been faced despite ongoing geopolitical issues. (Vikram Kelkar)
Product Pipelines & R&D
- Question: Which products are in the pipeline and what segments do they cater to? (Prerak Gandhi)
- Answer: There are three product pipelines: micronutrient premixes for food fortification; clinical and wellness nutrition under PentaSure with 12 brand extensions plus PediaGold for paediatrics; and the ESG segment covering RUTF, ready-to-use supplementary foods, and micronutrient powders. New products are expected to roll out soon as R&D remains a core backbone. (Nikhil Kelkar)
Growth Guidance & Segment Margins
- Question: Do you have volume growth and margin guidance? (Shravan)
- Answer: Management expects to maintain the same momentum as the last 2–3 years, with operating leverage driving further margin expansion as revenue grows. Segment-level margins: branded 60–68%, premix 35–40%, and ESG 25–30%. (Nikhil Kelkar)
Capacity Utilization Trajectory
- Question: Why is capacity utilization at ~30%, and how will it shape up? (Saket Kapoor)
- Answer: The blended figure reflects segment variation: branded operates at 50–60%, premix at 40–45%, and ESG at 35–40% (sometimes 60%) depending on order flow. The buffer is deliberately retained for future tenders and unanticipated orders; blended utilization is expected to range between 35–40% going forward. (Soman Jana)
Margin Doubling Over Four Years
- Question: What drove EBITDA margin doubling from 6.2% to 13.8% over four years? (Saket Kapoor)
- Answer: The primary driver was volume growth in the branded segment, which contributes more than 50% gross margin; the premix segment also provided strong bottom-line support. Both segments grew roughly 20–30% annually over the period, lifting overall EBITDA. (Soman Jana)
Competitive Landscape
- Question: Who are the key competitors in India and globally, and what is Hexagon's market share? (Nitin Khandkar)
- Answer: In the premix segment, competitors include DSM, Firmenich, BASF, and SternVitamin globally, with Piramal in India. Market share is difficult to quantify because the market blends single vitamins and premixes, but Hexagon holds one of the good shares in the specialized premix segment. (Vikram Kelkar)
Revenue Split & Long-Term Aspiration
- Question: Can you provide a revenue split by segment and the long-term aspiration over 3–5 years? (Nikhil Gupta)
- Answer: FY26 revenue split: branded ~30%, premix ~35–40%, ESG ~30%. Management confirmed that the historical trajectory of doubling revenue every 4–5 years is a correct estimate for the aspiration going forward. (Soman Jana; Nikhil Kelkar)
Branded Growth Strategy & Market Headroom
- Question: How do you plan to grow the branded segment beyond PentaSure, given the competitive intensity in Tier 1 cities? (Urvija Shah; Abhishek Maheshwari)
- Answer: The clinical nutrition market is ~₹6,300 crores, so Hexagon remains a small player with huge headroom. Strategy includes expanding medical representative teams, deepening Tier 2/3 distribution, building e-commerce across major portals and e-pharmacies, and increasing focus on PediaGold and Obesigo with sustained all-India promotion. (Nikhil Kelkar)
Raw Material Price Volatility (Whey)
- Question: How do you safeguard against rising whey prices and raw material volatility? (Urvija Shah)
- Answer: In the branded segment, price increases can be passed through via MRP revisions. For vitamins and other ingredients, strategic inventory is procured where required. Management confirmed no major impact so far. (Nikhil Kelkar)
Product Differentiation vs MNCs
- Question: What incentivizes a consumer to choose Hexagon over Abbott, Nestle, or Fresenius Kabi? (Dhanesh)
- Answer: Products are differentiated on formulation — for example, multi-protein blends (three or four proteins) offering distinct amino acid profiles — backed by stringent quality. This is reinforced by a medical representative team covering hospitals and clinics, participation in medical conferences, and scientific education programs for the medical fraternity. (Nikhil Kelkar)
Receivables Increase
- Question: Why did trade receivables rise from ₹60 crores to ₹82 crores? (Makool Agarwal)
- Answer: The increase is attributable to large ESG orders dispatched in Q3 and Q4, plus a domestic premix order jump dispatched largely in Q4. These are cyclical in nature and have now been normalized. (Soman Jana)
FY27 Outlook
- Question: Given the war situation, are we on track for the historical 15–20% growth in FY27? (Makool Agarwal)
- Answer: The war situation has not negatively impacted business to date, and management expects to continue the growth journey despite the West Asian conflict. (Vikram Kelkar)
Key Takeaway
Hexagon Nutrition delivered a landmark maiden listed year in FY26, with revenue from operations up 17.8% to ₹382.63 crores, EBITDA up 32.01% to ₹52.90 crores (13.83% margin), and PAT up 56.1% to ₹37.94 crores (9.9% margin), driven by branded segment volume growth, operating leverage, and manufacturing efficiencies. The portfolio is evenly balanced across premix (35–40% of revenue), branded clinical nutrition (30%), and ESG/therapeutic foods (~30%), with exports at 57% of revenue. Management guided to sustaining the historical ~15–20% growth trajectory (doubling revenue every 4–5 years) and further margin expansion, with capacity utilization improving to 35–40% from ~30%. Strategic priorities include scaling PediaGold and Obesigo, expanding Tier 2/3 distribution and e-commerce, and maintaining a healthy UN tender pipeline. Key watch points remain West Asia geopolitical exposure (<20% of exports), raw material price volatility, and normalization of elevated receivables.